Overview

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Status:
Not yet recruiting
Trial end date:
2025-03-17
Target enrollment:
Participant gender:
Summary
This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S